novavax logo

GAITHERSBURG, Md., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. NVX‑CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with Novavax’ proprietary Matrix‑M™.

“Novavax is in a leading position to significantly contribute to the need for safe and efficacious vaccines that will ultimately end the worldwide COVID-19 pandemic,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “We continue to make meaningful progress as we work to test, manufacture and ultimately deliver NVX-CoV2373 with unprecedented speed, as well as put partnerships in place that would ensure widespread and equitable access worldwide.”

 

MaximBio Product

Rockville, Maryland’s Maxim Biomedical (MaximBio) is on the cusp of bringing 3 million of its new and effective point-of-care COVID-19 tests to the fight against the coronavirus pandemic in early 2021, with a scale up to 15 million tests per month expected by Q2 2021. 

The company’s brand new point-of-care (POC), ready out-of-the-box antigen test is based on a Lateral Flow Assay technology (LFA) that produces visually interpreted results within 15 minutes. 

 

The Hemafuse device

BALTIMORE, United States of America, October 29, 2020/APO Group/ -- Sisu Global’s (SisuGlobal.health) flagship medical device is Hemafuse, a surgical autotransfusion device that is revolutionizing blood access across Africa. There is a global shortage of 100 millions units of donor blood worldwide, and only 40% of the demand for blood transfusions is met across Africa. The COVID-19 pandemic has dramatically worsened the global blood shortage as blood drives and large gatherings have been cancelled. Autotransfusion is the process of salvaging and retransfusing the patient's own blood in cases of internal bleeding. Studies show that autotransfusion reduces a patient’s recovery time and risk of infection and removes the potential for rejection when compared to donor blood. Notably, autotransfusion is viable for cases of ruptured ectopic pregnancy. Other viable cases include blunt trauma, traffic accidents, and cardiac and orthopedic surgeries.

 

AstraZeneca Logo

Late-stage trials showed that AstraZeneca’s coronavirus vaccine, which is being manufactured for the United States in Baltimore, was up to 90% effective, the English pharmaceutical company said Monday.

AstraZeneca’s vaccine candidate gives public health officials hope they may soon have access to a vaccine that is cheaper and easier to distribute than those of some of its rivals.

Even though the vaccine still needs regulatory approval, it’s already being made at Emergent BioSolutions’ plant in East Baltimore. The Gaithersburg-based contract drug manufacturer was named AstraZeneca’s U.S. manufacturing partner in June. The partnership was expanded in July and is now valued at $261 million.

 

Cover of Presentation

Join Rich Bendis, Pete Briskman and Ann Rutledge as they Discuss Securitization, Covid-19 and Political Analysis related to the BioHealth industry.

 

altimmune logo

GAITHERSBURG, Md., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to commence a Phase 1 clinical study of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID. AdCOVID is designed to stimulate a broad immune response including both systemic immunity (neutralizing antibody) and local immunity (mucosal IgA and resident memory T cells) in the nasal cavity and respiratory tract.

 

Carol Nacy and Rich Bendis

Listen now via Apple https://apple.co/374aOFI, Google https://bit.ly/3pTGqqj, Spotify https://bit.ly/3nIl7WO, and TuneIn https://bit.ly/3nIl7WO

Dr. Nacy co-founded our Sequella in 1997 and has served as our CEO and Chairman of the Board since 1999. Prior to Sequella, Dr. Nacy served during 1997 and 1998 as Chief Scientific Officer (CSO) for Anergen, Inc., a California company acquired by Corixa Corporation in December 1998. From 1993 through 1997, Dr. Nacy was Executive Vice President and CSO at EntreMed, Inc. and participated in its successful initial public offering in June 1996. Previously, Dr. Nacy was Career Scientist (GS-15) at the Walter Reed Army Institute of Research, Washington, DC. Dr. Nacy currently serves on the board of directors of companies and non-profit agencies.

Click here for the Transcript

BHIThanksgiving

 

Happy Thanksgiving from the BHI team!

OS Therapies  Logo

CAMBRIDGE, Md., Nov. 17, 2020 /PRNewswire/ -- OS Therapies, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat and cure Osteosarcoma (OS) and other deadly cancers in children and adults, today announced the acquisition of all indications for OST-HER2 (Listeria monocytogenes), including Canine. The technology that was developed and extensively tested at University of Pennsylvania, has been provisionally approved by the USDA for Osteosarcoma in canines. Phase I and Phase III trials conducted in canines have had very positive results.

 

Carol Nacy and Rich Bendis

Listen now via Apple https://apple.co/374aOFI, Google https://bit.ly/3pTGqqj, Spotify https://bit.ly/3nIl7WO, and TuneIn https://bit.ly/3nIl7WO

Dr. Nacy co-founded our Sequella in 1997 and has served as our CEO and Chairman of the Board since 1999. Prior to Sequella, Dr. Nacy served during 1997 and 1998 as Chief Scientific Officer (CSO) for Anergen, Inc., a California company acquired by Corixa Corporation in December 1998. From 1993 through 1997, Dr. Nacy was Executive Vice President and CSO at EntreMed, Inc. and participated in its successful initial public offering in June 1996. Previously, Dr. Nacy was Career Scientist (GS-15) at the Walter Reed Army Institute of Research, Washington, DC. Dr. Nacy currently serves on the board of directors of companies and non-profit agencies.

Click here for the Transcript

Immunomic Therapeutics logo

ROCKVILLE, Md. & DURHAM, N.C.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, and CoImmune, Inc. (“CoImmune”), a privately held clinical-stage immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, announced today that the companies have entered into a license agreement for ITI to use CoImmune’s proprietary dendritic cell process for certain ITI cell therapy vaccine programs. The partnership highlights the oncology pipeline of ITI and CoImmune’s expertise and technology in the development and manufacture of cell-based therapeutics.

 

Time Magazine Cover Image - The Best Inventions

BALTIMORE (WJZ) — TIME Magazine has named the Johns Hopkins University’s COVID-19 dashboard a top invention of 2020.

The Johns Hopkins Coronavirus Resource Center was called “2020’s Go-To Data Source” by the magazine. The dashboard, which reported Wednesday the U.S. recorded 250,000 coronavirus deaths, has tracked the spread of coronavirus around the world.

The annual list, which was announced Thursday, recognized 100 groundbreaking inventions that “are making the world better, smarter and even a bit more fun.”

Image: TIME

Oncolommune Logo

KENILWORTH, N.J., & ROCKVILLE, Md.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and OncoImmune, a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of OncoImmune for an upfront payment of $425 million in cash. In addition, OncoImmune shareholders will be eligible to receive sales-based payments and payments contingent on the successful achievement of certain regulatory milestones. OncoImmune recently announced positive top-line findings from an interim efficacy analysis of a Phase 3 study evaluating its lead therapeutic candidate CD24Fc for the treatment of patients with severe and critical COVID-19.

 

Emergent PBS

The race to develop vaccine candidates to prevent COVID-19 represents an unprecedented national and global effort. President Trump and some public health experts say encouraging early results from Pfizer and Moderna suggest the approach is working. But there are also questions about the risks of ramping up vaccine research and development at this scale and on this timeline. Miles O’Brien reports.

Image: https://www.pbs.org

Alexandria Special

PASADENA, Calif., Nov. 16, 2020 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT and the first, longest-tenured and pioneering owner, operator and developer uniquely focused on collaborative life science, technology and agtech campuses in AAA innovation cluster locations, today announced that Alexandria LaunchLabs® at the Alexandria Center® for Life Science in New York City is the first laboratory space in the world to achieve the WELL Health-Safety Rating for Facility Operations and Management. Building on its prior recognition as the world's first laboratory space to receive a WELL Certification for excellence in improving human health and well-being through building design, this latest evidence-based, third-party verified rating for the flagship location of Alexandria LaunchLabs—the premier startup platform accelerating the growth of early-stage life science companies—further affirms Alexandria's longstanding, robust and meticulous initiatives to help keep its tenants, employees, visitors, service providers and key industry stakeholders healthy and safe.

Image: Alexandria LaunchLabs® – New York City. Courtesy of Alexandria Real Estate Equities, Inc. 


Since cracking the Top 10 in 2016, UMD has climbed steadily in The Princeton Review's undergraduate entrepreneurship rankings, now ranking No. 6 overall in the 2021 rankings.
(Photo by Stephanie S. Cordle)

For the sixth consecutive year, the University of Maryland (UMD) earned a top 10 ranking in The Princeton Review’s annual survey of top schools for entrepreneurship. In the 2021 rankings released today and featured in the December issue of Entrepreneur magazine, UMD placed No. 6 for undergraduate entrepreneurship education—climbing one spot from last year—and No. 3 among public universities. UMD additionally was listed at No. 23 for graduate entrepreneurship education, marking the ninth consecutive year that the university has been named a top 25 program. 

Image: Since cracking the Top 10 in 2016, UMD has climbed steadily in The Princeton Review's undergraduate entrepreneurship rankings, now ranking No. 6 overall in the 2021 rankings. (Photo by Stephanie S. Cordle)

Accelerating Cures Logo

We offer six programs to accelerate discovery and commercialization of human stem cell-based technologies. Please verify eligibility, read the appropriate RFA below and apply here.

 

Event Cover Image

BLUE KNIGHT™, a collaboration between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority (BARDA), offers emerging life science companies an opportunity to join the JLABS incubator ecosystem with additional support from BARDA. BLUE KNIGHT™ companies, selected for their mutual alignment to Johnson & Johnson and BARDA areas of interest, may have an opportunity to receive additional support including fee assistance and mentorship. At JLABS @ Washington, DC and other select JLABS sites, BLUE KNIGHT™ companies will join the full breadth of Johnson & Johnson Innovation, including opportunities for funding, third-party services, educational events and access to R&D experts from medical technology, consumer healthcare product and Janssen pharmaceutical teams.

About Blue Knight

Johnson & Johnson Innovation – JLABS is collaborating with the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, to form Blue Knight.

This collaboration aims to stimulate innovation and incubation of technologies that improve health security and response through companies focused on public health threats and emerging infectious diseases. Find out more about BARDA and its mission at www.PHE.gov/BARDA.

If you are looking to learn more about the Johnson & Johnson Innovation – JLABS model, JLABS @ Washington, DC, BLUE KNIGHT™, mutual areas of interest between Johnson & Johnson and BARDA, and what the application process entails, join us for our Informational Session! We are currently accepting applications.

 

Northpond Ventures Logo

BOSTON--(BUSINESS WIRE)--Harvard University's Wyss Institute for Biologically Inspired Engineering has established its first research and innovation alliance by joining forces with Northpond Labs, the research and development-focused affiliate of a leading science and technology-driven venture capital firm, Northpond Ventures. Through the alliance, Northpond Labs will provide $12 million to create a Laboratory for Bioengineering Research and Innovation at the Wyss Institute and to support impactful research with strong translation potential.

 

Carl Grant, Angie Collier and Juan Pablo Segura discuss networking strategies at TEDCO's 2019 Entrepreneur Expo.

(Photo by Karuga Koinange)

Maryland organizations are building an AI-powered web platform where entrepreneurs can find all of the resources available to them in the state.

It’ll be called the Maryland Entrepreneur Hub, EcoMap Technologies CEO Pava LaPere said this week.

TEDCO, the quasi-public agency that supports early-stage tech companies, recently selected the Baltimore-based EcoMap to build the platform after a formal RFP. Maryland Department of Commerce and University System of Maryland are also partnering on the effort.

Image: Carl Grant, Angie Collier and Juan Pablo Segura discuss networking strategies at TEDCO's 2019 Entrepreneur Expo. (Photo by Karuga Koinange)

Gary Disbrow - New BARDA Director

I am pleased to announce today the selection of Gary Disbrow, PhD, as Deputy Assistant Secretary for Preparedness and Response and Director of the Biomedical Advanced Research and Development Authority (BARDA). BARDA, a component of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, invests in the innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures – vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products – needed to combat 21st century health security threats. 

 

Johnson and Johnson Innovation Logo

With COVID-19, we’ve seen our preparedness response tested, and the question remains, how can we be better prepared to protect some of the most vulnerable members of our communities, our babies and children, from future threats? Unfortunately, less innovation takes place in the pediatric space due barriers in the discovery and development environment, including, ethical dilemmas, and regulatory requirements.

How can innovators work to develop pediatric therapeutics, diagnostics, vaccines, and other technologies that may protect the smallest members of society during a pandemic? Join us as we sit with key thought leaders, innovators and game-changers in the pediatrics space to discuss what is being done to develop groundbreaking medical countermeasures that aim to prepare and protect pediatric populations from the health threats of today – and those imagined and unimagined of tomorrow.

 

Aberdeen Proving Group, Md Building

ABERDEEN PROVING GROUND, Md. -- The U.S. Army signed a new cooperative agreement with Johns Hopkins University Sept. 30, 2020, to advance materials research using artificial intelligence and machine learning.

Researchers from the U.S. Army Combat Capabilities Development Command (DEVCOM) Army Research Laboratory will collaborate with Johns Hopkins faculty and students on four focused projects:

  • Using artificial intelligence to accelerate the iterative materials design cycle by high-throughput microstructural characterization and rapid processing 
  • Acoustic signature and reconstruction of defect avalanches in metals 
  • Real-time monitoring of laser-material interactions 
  • Toward self-repairing devices: Data-directed design of active, hierarchical colloidal assembly and reconfiguration

Image: https://www.army.mil/article/240874/army_teams_with_johns_hopkins_to_advance_materials_research

UK Flag

For decades, the United States and the United Kingdom have enjoyed a special relationship that crosses political, economic, and military lines. But, the two nations also share a similar comradery in the Life Sciences arena, and prominent biotech hubs like the BioHealth Capital Region and Philadelphia showcase that connection.

There are several similarities between the BioHealth Capital Region, Philadelphia, and the U.K. They all have vital programs in gene and cell therapy. And they are home to key government institutions. The Midlands in the U.K. is home to the National Health Service and multiple academic and commercial institutions. Maryland is home to the U.S. Food and Drug Administration, the National Institutes of Health, and other government agencies. The U.S. region is also home to multiple significant academic and commercial institutions as well. Most recently, decades-old messenger RNA work originating out of Philadelphia’s University of Pennsylvania is a major contributor to Moderna’s COVID vaccine.

 

Maryland Future 20

Following a statewide search to identify Maryland’s most innovative start-up companies with the potential to be the state’s next major business success story, Governor Larry Hogan today announced Maryland’s Future 20.

The Maryland Future 20 is part of Innovation Uncovered, an ongoing initiative by the Maryland Department of Commerce to highlight the state’s talented innovators, entrepreneurs, and growing small businesses. The search for the Future 20 garnered 125 nominations from the business community and general public. The list was selected based on a variety of factors, including innovation, future growth potential, the company’s Maryland story, and “wow” factor.

 

Y-shaped proteins called antibodies are vital for attacking and destroying the virus. Dr_Microbe/Getty Images - ROYALTY FREE

When President Trump was diagnosed with COVID-19, one of the cutting-edge experimental therapies he received was a mixture of monoclonal antibodies. But now a vaccine may soon be available. So are other therapies necessary or valuable? And what exactly is a monoclonal antibody?

Over the past few months, the public has learned about many treatments being used to combat COVID-19. An antiviral like remdesivir inhibits the virus from replicating in human cells. Convalescent plasma from the blood of donors who have recovered from COVID-19 may contain antibodies that suppress the virus and inflammation. Steroids like dexamethasone may modify and reduce the dangerous inflammatory damage to the lungs, thereby slowing respiratory failure.

Image: Y-shaped proteins called antibodies are vital for attacking and destroying the virus. Dr_Microbe/Getty Images - ROYALTY FREE

SR One Logo

SR One, a trans-Atlantic biotech venture capital firm, announced today the close of its first independent fund, having recently completed its spinout from GlaxoSmithKline (GSK). GSK is the largest investor in the oversubscribed $500 million fund, joined by a global pool of institutional asset managers, endowments, foundations, pension funds and family offices. SR One will seek to continue to build elite biotechnology companies developing innovative medicines that address significant unmet needs.

 

Samsung Biologics will pour 1.7 trillion won into its new Plant 4

South Korea’s leading biologics companies will invest hundreds of billions of won to building additional plants that would push the total amount of private investments for the biohealth industry to 10 trillion won by 2023.

Samsung Biologics will pour 1.7 trillion won into its new Plant 4 while Celltrion will invest 500 billion won to its Global Life Science Research Lab and Plant 3, all in Songdo, Incheon.

As its action plan for a more robust bio-industry ecosystem, the Government also pledged a 1.7 trillion won budget in 2021, up 30 percent from last year’s. The budget will prioritize pharmaceuticals, medical devices, and digital health care.

Image: Samsung Biologics will pour 1.7 trillion won into its new Plant 4 - https://www.econotimes.com

NewImage

Pantheon 2020 on Thursday, December 3, will feature breakout sessions, including "Diversity & Disruption: How 2020 Will Make Life Sciences Stronger".

Join us as we discuss how everyone in life sciences can approach diversity and inclusion from end-to-end to create a sustainable path forward for all of us and a new blueprint for life sciences success.

The state of AI in 2020 - Report Title

The results of this year’s McKinsey Global Survey on artificial intelligence (AI) suggest that organizations are using AI as a tool for generating value. Increasingly, that value is coming in the form of revenues. A small contingent of respondents coming from a variety of industries attribute 20 percent or more of their organizations’ earnings before interest and taxes (EBIT) to AI. These companies plan to invest even more in AI in response to the COVID-19 pandemic and its acceleration of all things digital. This could create a wider divide between AI leaders and the majority of companies still struggling to capitalize on the technology; however, these leaders engage in a number of practices that could offer helpful hints for success. And while companies overall are making some progress in mitigating the risks of AI, most still have a long way to go.

Blue Shield

In seeking to combat emerging infectious diseases and other 21st century health threats, the path to better prepared, protected, and healthy individuals, families, and communities could rely on unlocking the collective power of the global community. BLUE KNIGHT™ seeks to answer this call.

On December 8-10, Johnson & Johnson Innovation - JLABS and BARDA will virtually convene the emerging Blue Knight community of thought leaders, innovators and entrepreneurs for a three-day symposium, including interactive sessions focused on key areas of interest in infectious disease, public health, and company acceleration. Sessions will explore high priority areas of interest for scientific and technological innovation aimed for improving our preparedness and response to emerging health security threats.

Image: https://blueknightsymposium2020.splashthat.com/

scientist

Over the past nine months, more than $7 billion in federal funding has poured into the BioHealth Capital Region aimed at the battle against COVID-19 and has shown a spotlight on the broad impact biopharma life science companies and academic institutions are making in the fight against the pandemic.

“The moons are aligned over the BioHealth Capital Region right now and people are beginning to see how important the region is in helping to address the research development and manufacturing needs to address this dreaded disease,” said Richard Bendis, president and chief executive officer of BioHealth Innovation.

 

Stanley Erck

Novavax Inc. has the option to raise up to $500 million in a possible stock offering as it shepherds its Covid-19 vaccine candidate through clinical trials, juggles its seasonal flu vaccine program and sees its stock sustain dramatic highs.

The Gaithersburg biotech said it could offer up to 5.37 million shares of common stock based on its Nov. 5 closing price of $93.11, according to documents filed Tuesday with the Securities and Exchange Commission. That follows Novavax’s sale earlier this year of 3.4 million shares of common stock, which brought in $238.3 million in net proceeds.

 

Qiagen Logo

Qiagen NV QGEN, -2.76% shares rose in the extended session Wednesday after the Netherlands-based medical diagnostics company said it will begin selling a portable COVID-19 test in the United States. Qiagen shares rose 4% after hours, following a 0.9% rise in the regular session to close at $46.51. Called the “QIAreach SARS-CoV-2 Antigen Test,” the company said the test can process up to 30 swab samples to detect antigens of SARS-CoV-2, the virus that causes COVID-19, in people who are actively infected with the virus in up to 15 minutes. The test was developed by Qiagen in partnership with Australian digital diagnostics company Ellume. Qiagen said the QIAreach “will be particularly valuable when vaccines are introduced.”